Juan M O Connor1, Fernando Sanchez Loria2, Victoria Ardiles3, Jorge Grondona4, Pablo Sanchez5, Oscar Andriani6, Martin Fauda7, Fernando Brancato2, Eduardo Huertas2, Fernando Alvarez8, Eduardo de Santibañes9. 1. GI Clinical Oncology, Instituto Alexander Fleming, Buenos Aires, Argentina. 2. Surgical Oncology Department, Instituto Alexander Fleming, Buenos Aires, Argentina. 3. Hepato-Pancreato-Biliary & Liver Transplant, General Surgery Service, Hospital Italiano de Buenos Aires, Argentina. 4. Hospital de San Isidro, Buenos Aires, Argentina. 5. Surgical Department, Instituto de Oncologia Angel Roffo, Buenos Aires, Argentina. 6. Hepato-Pancreato-Billiary Sections, Sanatorio Los Arcos, Buenos Aires, Argentina. 7. Hepato-Pancreato-Billiary Department, Hospital Universitario Austral, Pilar, Argentina. 8. Hepato-Pancreato-Biliary Surgery, Clinica Universitaria Reina Fabiola, Cordoba, Argentina. 9. FACS, Hepato-Pancreato-Biliary & Liver Transplant, General Surgery Service, Hospital Italiano de Buenos Aires, Argentina.
Abstract
Aim: To determine the impact of KRAS mutation status on survival in patients undergoing surgery for colorectal liver metastases (CLM). Patients & methods: Patients with resected CLM and KRAS mutations. Survival was compared between mt-KRAS and wt-KRAS. Results: Of 662 patients, 174 (26.3%) were mt-KRAS and 488 (73.7%) wt-KRAS. mt-KRAS patients had significantly lower recurrence-free survival (HR: 1.42; 95% CI: 1.10-1.84). There were no differences between the groups for sidedness. Poorer survival was associated with mt-KRAS with positive lymph nodes, >1 metastases, tumors >5 cm, synchronous tumors and R1-R2. Conclusion: KRAS mutation status can help predict recurrence-free survival. Primary tumor location was not a prognostic factor after resection. KRAS mutation status can help design a multidisciplinary approach after curative resection of CLM.
Aim: To determine the impact of KRAS mutation status on survival in patients undergoing surgery for colorectal liver metastases (CLM). Patients & methods: Patients with resected CLM and KRAS mutations. Survival was compared between mt-KRAS and wt-KRAS. Results: Of 662 patients, 174 (26.3%) were mt-KRAS and 488 (73.7%) wt-KRAS. mt-KRASpatients had significantly lower recurrence-free survival (HR: 1.42; 95% CI: 1.10-1.84). There were no differences between the groups for sidedness. Poorer survival was associated with mt-KRAS with positive lymph nodes, >1 metastases, tumors >5 cm, synchronous tumors and R1-R2. Conclusion:KRAS mutation status can help predict recurrence-free survival. Primary tumor location was not a prognostic factor after resection. KRAS mutation status can help design a multidisciplinary approach after curative resection of CLM.